Fred H. Mermelstein
Fundador en Pear Tree Pharmaceuticals, Inc. .
Perfil
Fred H.
Mermelstein is the founder of Pear Tree Pharmaceuticals, Inc. (founded in 2007) where he holds the title of Chairman.
He was also the founder of PolaRx Biopharmaceuticals (founded in 1997) where he held the title of Director & Chief Scientific Officer.
Additionally, he was the founder of Javelin Pharmaceuticals, Inc. (founded in 1998) where he held the title of Director.
Dr. Mermelstein currently holds the position of Director at NX Development Corp., The Rogosin Institute, Inc., SanaRx Biotherapeutics, Inc., and NextRNA Therapeutics, Inc.Dr. Mermelstein has held former positions as President & Chief Executive Officer at Innovative Drug Delivery Systems, Inc. (1998-2003), Chairman at Correvio Pharma Corp., Chairman at Jordan Heart Foundation, Director at Fennec Pharmaceuticals, Inc. (2002-2009), Director-Venture Capital at Paramount Capital Investments LLC (2003), Director at Candel Therapeutics, Inc., and General Partner at Orion Biomedical Gp LLC.
Dr. Mermelstein obtained a doctorate degree from the University of Medicine & Dentistry of New Jersey and Rutgers State University of New Jersey.
Cargos activos de Fred H. Mermelstein
Empresas | Cargo | Inicio |
---|---|---|
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | Fundador | 24/07/2009 |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | Director/Miembro de la Junta | - |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | Director/Miembro de la Junta | - |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA. | Director/Miembro de la Junta | - |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Fred H. Mermelstein.
Empresas | Cargo | Fin |
---|---|---|
CANDEL THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/11/2018 |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Fundador | 02/07/2010 |
FENNEC PHARMACEUTICALS INC. | Director/Miembro de la Junta | 07/07/2009 |
Innovative Drug Delivery Systems, Inc.
Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. | Director Ejecutivo | 01/07/2003 |
░░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formación de Fred H. Mermelstein.
University of Medicine & Dentistry of New Jersey | Doctorate Degree |
Rutgers State University of New Jersey | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
FENNEC PHARMACEUTICALS INC. | Health Technology |
CANDEL THERAPEUTICS, INC. | Health Technology |
Empresas privadas | 12 |
---|---|
Orion Biomedical Gp LLC | |
Innovative Drug Delivery Systems, Inc.
Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology IDDS is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical need in the pain management market. IDDS’s product candidates address the market segment for prescription medications focused on treating acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post operative pain, orthopedic injury, procedural pain, burn pain and trauma. The product candidates offer enhanced pain relief, fewer adverse side effects and faster relief of pain compared to other currently available treatments. | Health Technology |
Correvio Pharma Corp.
Correvio Pharma Corp. Pharmaceuticals: MajorHealth Technology Correvio Pharma Corp. operates as a pharmaceutical company, which engages in the provision of development and commercialization of medical products. It operates through the Europe and Rest of the World geographical segments. The firm focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease. It offers the Brinavess and Aggrastat products to customers such as physicians, patients and healthcare systems. The company was founded in 1986 and is headquartered in Vancouver, Canada. | Health Technology |
Pear Tree Pharmaceuticals, Inc.
Pear Tree Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Pear Tree Pharmaceuticals, Inc. operates as a development stage company with interests in developing prescription products for women. It offers products that treat and prevent diseases, symptoms, and conditions associated with menopause and cancer chemotherapy. The company was founded by Stephen Charles Rocamboli, Fred H. Mermelstein, Janet Chollet and Martin J. Driscoll in July 2007 and is headquartered in Auburndale, MA. | Health Technology |
NX Development Corp.
NX Development Corp. Medical SpecialtiesHealth Technology NX Development Corp. operates as a life science company. It develops Gleolan oral solutions which helps in identifying malignant glioma, a type of brain tumor in adult patients. It allows surgeons to visualize brain tumors during surgery. The company was founded by Alan Ezrin and is headquartered in Lexington, KY. | Health Technology |
PolaRx Biopharmaceuticals
PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Part of Swedish Orphan Biovitrum AB, PolaRx Biopharmaceuticals is a company that manufactures TriOxide drugs for the treatment of leukemia and other cancers. The company is based in New York, NY. The company was founded by Fred H. Mermelstein, Peter Morgan Kash, Raymond P. Warrell. PolaRx Biopharmaceuticals was acquired by CTI BioPharma Corp., part of Swedish Orphan Biovitrum AB from June 27, 2023 on January 13, 2000 for $17.50 million. | Commercial Services |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA. | Health Technology |
The Rogosin Institute, Inc.
The Rogosin Institute, Inc. Medical/Nursing ServicesHealth Services The Rogosin Institute, Inc. engages in providing treatment for kidney diseases. The company was founded in 1983 and is headquartered in New York, NY. | Health Services |
Paramount Capital Investments LLC | |
SanaRx Biotherapeutics, Inc.
SanaRx Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology SanaRx Biotherapeutics, Inc. is a biotechnology company. It serves patients with orphan diseases of the alimentary tract. The company is headquartered in Medford, MA. | Health Technology |
NextRNA Therapeutics, Inc.
NextRNA Therapeutics, Inc. BiotechnologyHealth Technology NextRNA Therapeutics, Inc. is a biotechnology company that specializes in drug development services. The company is based in Cambridge, MA. The company was founded in 2021 by Leon Wert-Lamas, Marc A. Cohen, Julia Novina, Carl Novina, Dominique Verhelle, Kenneth C. Anderson, Robert S. Langer. Dominique Verhelle has been the CEO since 2021. | Health Technology |
Jordan Heart Foundation |
- Bolsa de valores
- Insiders
- Fred H. Mermelstein